Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Dianthus projects funding into 2030 as clinical development spending rises and its next Phase 2 readout approaches in December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) reported a third-quarter 2026 net loss of $46.6 million while advancing its autoimmune disease trials.
Loss widened from $36.8 million a year earlier, while loss per share narrowed to $0.81 from $0.97. Research and development expenses rose to $45.6 million from $32.5 million. Cash, cash equivalents and investments totaled approximately $1.2 billion at September 30; the company projects funding into 2030.
An interim analysis of the first 40 participants completing open-label CAPTIVATE Part A in chronic inflammatory demyelinating polyneuropathy showed a 75% response rate, above the target of 50% or greater. Dianthus expects MMN Phase 2 results in December 2026, CAPTIVATE Part A results by year-end 2027 and Part B by year-end 2028, and Phase 3 generalized myasthenia gravis results in the second half of 2028. DNTH212 began dosing lupus patients in October.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Cash, cash equivalents and investments of approximately $1.2 billion support projected runway into 2030.
- Moderate pointCAPTIVATE interim response reached 75% among the first 40 open-label Part A completers, versus a target of 50% or greater.
- Minor pointCAPTIVATE interim safety showed no related serious infections or serious adverse events, clinical drug-induced lupus symptoms, or safety discontinuations.
- Minor point. Forward-looking: it has not happened yet and may not happen.CAPTIVATE Part A is conservatively projected to need less than 200 participants to randomize 128 responders into Part B.
- Minor point. Forward-looking: it has not happened yet and may not happen.CAPTIVATE top-line results are expected by year-end 2027 for Part A and by year-end 2028 for Part B.
9 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.EMERGE Phase 3 began in June 2026; top-line generalized myasthenia gravis results are expected in the second half of 2028.
- Minor pointMaGic open-label extension results demonstrated sustained efficacy and a continued favorable safety profile in generalized myasthenia gravis.
- Minor point. Forward-looking: it has not happened yet and may not happen.MoMeNtum enrolled 46 patients, exceeding its original 36-patient target; Phase 2 MMN results are expected in December 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.MMN Phase 3 initiation is planned for 2027, following Phase 2 top-line results.
- Minor point. Forward-looking: it has not happened yet and may not happen.DNTH212 Phase 1 lupus patient dosing began in October; preliminary Part B results are expected in the second half of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.DNTH212 preliminary Phase 1 single-dose healthy-volunteer results are expected in the first quarter of 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.DNTH212 multiple-dose Phase 1 initiation outside China is planned for the second quarter of 2027, with preliminary data expected that second half.
- Minor point. Forward-looking: it has not happened yet and may not happen.DNTH212 development updates for Sjögren’s disease, lupus and dermatomyositis are planned by year-end 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.DNTH312 remains on track to be Phase 1 ready by year-end 2027.
Negative
- Moderate pointQuarterly net loss widened to $46.6 million from $36.8 million year over year; basic and diluted loss per share narrowed to $0.81 from $0.97.
- Minor pointQuarterly research and development expenses rose to $45.6 million from $32.5 million year over year.
- Minor pointQuarterly general and administrative expenses rose to $14.1 million from $8.2 million year over year.
News Explained
Dianthus projects that CAPTIVATE’s open-label Part A will require fewer than 200 participants to yield 128 responders for randomization into placebo-controlled Part B; these are projected enrollment figures, not reported completed counts.
Key Figures
- CAPTIVATE interim response rate
- 75% among the first 40 participants
- Part A responder analysis; above the stated target of 50% or greater
- CAPTIVATE Part A and Part B enrollment
- Less than 200 participants in Part A to randomize 128 responders into Part B
- Phase 3 CIDP trial design projection
- MoMeNtum enrollment
- 46 patients
- Phase 2 MMN top-line results on track for December 2026
- Cash, cash equivalents and investments
- $1.2 billion
- As of September 30, 2026; projected runway into 2030
- R&D expenses
- $45.6 million vs. $32.5 million
- Quarter ended September 30, 2026 vs. September 30, 2025
- G&A expenses
- $14.1 million vs. $8.2 million
- Quarter ended September 30, 2026 vs. September 30, 2025
- Net loss
- $46.6 million vs. $36.8 million
- Quarter ended September 30, 2026 vs. September 30, 2025
Previous Earnings Reports
-
Reported Q3 results and clinical-program updates; current report compares Q3 R&D expenses and net loss with those results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
single ascending dose medical
multiple ascending dose medical
placebo-controlled withdrawal medical
orphan drug designation regulatory
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28
Phase 3 CAPTIVATE trial of claseprubart in CIDP evaluating 300mg/2mL Q2W now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study, with Part A top-line results expected by YE’27 and Part B top-line results expected by YE’28
Phase 2 MoMeNtum trial of claseprubart in MMN top-line results on track for December ’26
DNTH212 continues to advance with Phase 1 single ascending dose (SAD) Part A healthy volunteer preliminary data expected in Q1’27. First SLE patient in Part B of the Phase 1 SAD study was dosed in October, with preliminary results from Part B expected in 2H’27. The Dianthus-led Phase 1 multiple ascending dose (MAD) study is planned to initiate in Q2’27 with preliminary data expected in 2H’27
DNTH312, an internally developed, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL for severe autoimmune diseases, on track to be Phase 1 ready by YE’27
Approximately
NEW YORK and WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today reported financial results for the third quarter ending September 30, 2026, and provided an update on other recent business achievements.
“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “Following top-line results from our Phase 2 MoMeNtum trial of claseprubart in December, we plan to quickly initiate a Phase 3 trial in MMN in 2027. MMN represents a significant market opportunity, characterized by high unmet needs and limited competition. IVIg is the only approved treatment for patients with MMN, and the lack of patient and physician satisfaction with IVIg presents a meaningful opportunity for claseprubart, given its unique potential for a differentiated, best-in-disease profile due to potent inhibition of the classical pathway and preservation of the lectin and alternative pathways while targeting a patient-friendly, 300mg/2mL, self-administered subcutaneous autoinjector once every two weeks.”
Claseprubart: Potential Best-in-Disease aC1s Inhibitor for Neuromuscular Diseases
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks. Claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Generalized Myasthenia Gravis (gMG)
- Phase 3 EMERGE trial on track with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June, with top-line results expected in 2H’28.
- MaGic OLE data presented at AANEM: Results from the Phase 2 MaGic open-label extension (OLE) were presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, September 29 to October 2, 2026, and demonstrated sustained efficacy and a continued favorable safety profile for claseprubart in gMG.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial, exceeding the target response rate of50% or greater based on precedent set with aC1s inhibition. Results were consistent and clinically meaningful across multiple efficacy measures. Claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of drug-induced lupus (DIL), no related serious adverse events (SAEs) or discontinuations due to safety.- CAPTIVATE Part A top-line results expected by YE’27 and Part B top-line results expected by YE’28: The Phase 3 CAPTIVATE trial of claseprubart 300mg/2mL S.C. Q2W is now conservatively projected to require less than 200 participants in the open-label Part A in order to randomize 128 responders into the placebo-controlled withdrawal Part B portion of the study. Top-line results from all participants completing Part A are expected by YE’27, and top-line results from Part B are expected by YE’28.
Multifocal Motor Neuropathy (MMN)
- Phase 2 MoMeNtum trial top-line results on track for December ’26: The MoMeNtum trial, a global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN, exceeded its original enrollment target of 36 patients. Top-line results with 46 patients are on track for December ’26. Following top-line results, a Phase 3 trial in MMN is planned to initiate in 2027.
All Programs
- Multiple claseprubart data presentations were made at the 18th International Congress on Neuromuscular Diseases (ICNMD), American Academy of Neurology (AAN) Autoimmune Neurology Conference, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, and American Neurological Association (ANA) Annual Meeting. Among the data presented were results demonstrating a sustained safety and efficacy profile for claseprubart in the Phase 2 MaGic open-label extension, and a
75% response rate observed in the interim responder analysis of the first 40 participants completing unblinded Part A of the Phase 3 CAPTIVATE trial. Presentations are available in the Investors section of the Dianthus website.
DNTH212: Potential Best-in-Disease, Bifunctional BDCA2 and BAFF/APRIL Inhibitor for Rheumatology Conditions
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes.
- Dosing of SLE patients in Phase 1 Part B initiated in October: DNTH212 is being evaluated in a two-part Phase 1 study in China in healthy volunteers (Part A) and patients with Systemic Lupus Erythematosus (SLE, Part B). Part A is evaluating single ascending doses of DNTH212, with preliminary healthy volunteer data expected in Q1’27. Based upon data seen to date and as previously announced by Leads Biolabs, dosing of SLE patients in Part B of the Phase 1 SAD study was initiated in October, with preliminary Part B SLE data expected in 2H’27.
- Dianthus-led MAD study planned to initiate in Q2’27: Dianthus plans to initiate a Phase 1 multiple ascending dose (MAD) study outside of China in healthy volunteers in Q2’27 to support the continued global development of DNTH212, with preliminary data expected in 2H’27.
- Update on next steps in prioritized indications by YE’27: Dianthus plans to provide an update on next steps for advancing its first three prioritized indications of Sjögren’s Disease (SjD), SLE, and Dermatomyositis (DM) in clinical development by YE’27.
DNTH312 is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. By targeting two validated pathways with complementary disease-modifying mechanisms, DNTH312 expands Dianthus’ leadership position in autoimmune diseases with its potential for best-in-disease efficacy by targeting deeper responses and broader symptom control, while also addressing larger patient populations.
- DNTH312 is on track to be Phase 1 ready by YE’27.
Corporate Updates
- Dianthus was selected by Great Place To Work® and Fortune magazine for the 2026 Fortune Best Workplaces in BioPharma™ List. This was Dianthus’ inaugural appearance on the list, ranking among the top 30 small- and medium-sized biotechnology and pharmaceutical companies in the United States. The Company was recognized for fostering a high-trust and engaging workplace culture.
Third-Quarter 2026 Financial Results
- Cash Position – Approximately
$1.2 billion of cash, cash equivalents and investments as of September 30, 2026, is projected to provide runway into 2030. - R&D Expenses – Research and development (R&D) expenses for the quarter ended September 30, 2026 were
$45.6 million , inclusive of$6.3 million of stock-based compensation, compared to$32.5 million for the quarter ended September 30, 2025, which included$2.5 million of stock-based compensation. This increase in R&D expenses was primarily driven by higher clinical costs and increased headcount to support claseprubart Phase 2 and Phase 3 development, in addition to costs related to DNTH212 and DNTH312 development. - G&A Expenses – General and administrative (G&A) expenses for the quarter ended September 30, 2026 totaled
$14.1 million , inclusive of stock-based compensation of$6.4 million , compared to$8.2 million for the quarter ended September 30, 2025, which included$3.3 million of stock-based compensation. This increase in G&A expenses was primarily due to increased headcount. - Net Loss – Net loss for the quarter ended September 30, 2026 was
$46.6 million or$0.81 per share (basic and diluted), compared to$36.8 million or$0.97 per share (basic and diluted) for the quarter ended September 30, 2025. - Additional Information – For additional information on the Company’s financial results for the quarter ended September 30, 2026, please refer to the Form 10-Q filed with the SEC.
About Claseprubart (DNTH103)
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis in May 2026.
Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, report top-line results from the Phase 3 CAPTIVATE trial Part A in CIDP by YE’27 and from Part B by YE’28, and report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.
Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About DNTH212
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. Dianthus is building a rheumatology franchise with DNTH212 and has selected Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM) as the first three prioritized indications for clinical development. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with SLE (Part B) is ongoing, with preliminary healthy volunteer data expected in Q1’27 and preliminary Part B SLE data expected in 2H’27. Dianthus plans to initiate a Phase 1 multiple ascending dose (MAD) study outside of China in healthy volunteers in Q2’27 to support the continued global development of DNTH212, with preliminary data expected in 2H’27. Dianthus plans to provide an update on next steps for advancing its first three prioritized indications in clinical development by YE’27.
DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About DNTH312
DNTH312 is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. DNTH312 is enhanced with YTE half-life extension technology, similar to claseprubart. By targeting two validated pathways with complementary disease-modifying mechanisms, DNTH312 is designed to expand Dianthus’ leadership position in autoimmune diseases with potential for best-in-disease efficacy by targeting deeper responses and broader symptom control, while also addressing larger patient populations. DNTH312 is on track to be Phase 1 ready by YE’27.
DNTH312 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart, DNTH212, and DNTH312, and any developments or results in connection therewith, including the target product profile and administration of claseprubart, DNTH212, and DNTH312; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential market opportunities, in particular with respect to claseprubart, DNTH212, and DNTH312. Claseprubart, DNTH212, and DNTH312 are investigational agents that are not approved as therapies in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart, DNTH212, and DNTH312 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open-label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart, DNTH212, or DNTH312 may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
| DIANTHUS THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 55,686 | $ | 51,087 | ||||
| Short-term investments | 782,097 | 353,208 | ||||||
| Accounts receivable, net | 582 | 52 | ||||||
| Prepaid expenses and other current assets | 17,673 | 5,091 | ||||||
| Total current assets | 856,038 | 409,438 | ||||||
| Long-term investments | 406,040 | 110,135 | ||||||
| Property and equipment, net | 749 | 296 | ||||||
| Right-of-use operating lease assets | 1,151 | 1,337 | ||||||
| Other assets and restricted cash | 12,274 | 9,716 | ||||||
| Total assets | $ | 1,276,252 | $ | 530,922 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,498 | $ | 9,725 | ||||
| Accrued expenses | 21,079 | 19,452 | ||||||
| Current portion of deferred revenue | 1,589 | 1,188 | ||||||
| Current portion of operating lease liabilities | 349 | 367 | ||||||
| Total current liabilities | 28,515 | 30,732 | ||||||
| Deferred revenue | 5,449 | 5,770 | ||||||
| Long-term operating lease liabilities | 859 | 1,019 | ||||||
| Total liabilities | 34,823 | 37,521 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 56 | 43 | ||||||
| Additional paid-in capital | 1,722,069 | 829,598 | ||||||
| Accumulated deficit | (474,421 | ) | (336,729 | ) | ||||
| Accumulated other comprehensive (loss)/income | (6,275 | ) | 489 | |||||
| Total stockholders’ equity | 1,241,429 | 493,401 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,276,252 | $ | 530,922 | ||||
| DIANTHUS THERAPEUTICS, INC. | |||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (unaudited) | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Revenues: | |||||||||||||||||
| License revenue | $ | 1,210 | $ | 396 | $ | 2,434 | $ | 1,752 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 45,600 | 32,489 | 128,814 | 85,743 | |||||||||||||
| General and administrative | 14,082 | 8,195 | 40,107 | 24,401 | |||||||||||||
| Total operating expenses | 59,682 | 40,684 | 168,921 | 110,144 | |||||||||||||
| Loss from operations | (58,472 | ) | (40,288 | ) | (166,487 | ) | (108,392 | ) | |||||||||
| Other income/(expense): | |||||||||||||||||
| Interest and investment income | 12,143 | 3,658 | 29,950 | 10,852 | |||||||||||||
| Gain/(loss) on investment in former related party | 28 | 227 | (169 | ) | 254 | ||||||||||||
| Loss on currency exchange, net | (24 | ) | (2 | ) | (49 | ) | (54 | ) | |||||||||
| Other expense | (318 | ) | (360 | ) | (937 | ) | (565 | ) | |||||||||
| Total other income | 11,829 | 3,523 | 28,795 | 10,487 | |||||||||||||
| Net loss | $ | (46,643 | ) | $ | (36,765 | ) | $ | (137,692 | ) | $ | (97,905 | ) | |||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.81 | ) | $ | (0.97 | ) | $ | (2.56 | ) | $ | (2.68 | ) | |||||
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted | 57,341,193 | 37,794,088 | 53,835,116 | 36,476,370 | |||||||||||||
| Comprehensive loss: | |||||||||||||||||
| Net loss | $ | (46,643 | ) | $ | (36,765 | ) | $ | (137,692 | ) | $ | (97,905 | ) | |||||
| Other comprehensive (loss)/income: | |||||||||||||||||
| Unrealized (loss)/gain on marketable securities | (4,147 | ) | 65 | (6,764 | ) | 57 | |||||||||||
| Total other comprehensive (loss)/income | (4,147 | ) | 65 | (6,764 | ) | 57 | |||||||||||
| Total comprehensive loss | $ | (50,790 | ) | $ | (36,700 | ) | $ | (144,456 | ) | $ | (97,848 | ) | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.